Silence Therapeutics (SLN) Net Cash Flow (2024 - 2026)
Silence Therapeutics (SLN) posted Net Cash Flow of -$5.6 million for Q1 2026, up 92.07% sequentially from -$70.7 million in Q4 2025, and up 90.11% YoY from -$2.9 million in Q1 2025.
Silence Therapeutics (SLN) Net Cash Flow (2024 - 2026) Analysis & Trends
Silence Therapeutics has reported Net Cash Flow for 3 years, with the latest figure at -$5.6 million in Q1 2026.
- Quarterly Net Cash Flow rose 90.11% year-over-year to -$5.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59.2 million (up 24.26% YoY) and the FY2025 annual result came in at -$110.3 million, down 310.13% from the prior year.
- Net Cash Flow improved to -$5.6 million in Q1 2026 per SLN's latest filing, from -$70.7 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $74.0 million in Q1 2024 and troughed at -$70.7 million in Q4 2025.
- A 3-year average of -$7.0 million and a median of -$5.6 million in 2026 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 172.44% in 2025, down 448.3% in 2025.
- Over 3 years, Net Cash Flow stood at $38.5 million in 2024, then slumped by 283.3% to -$70.7 million in 2025, then surged by 92.07% to -$5.6 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$5.6 million, -$70.7 million, and $40.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Silence Therapeutics | 648.22 Mn | 576.12 Mn | - | 66.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66.45 Mn |
| Jun 30, 2026 | 66.45 Mn |
| Mar 31, 2026 | -5.60 Mn |
| Mar 31, 2026 | -5.60 Mn |
| Dec 31, 2025 | -70.65 Mn |
| Dec 31, 2025 | -70.65 Mn |
| Sep 30, 2025 | 40.41 Mn |
| Sep 30, 2025 | 40.41 Mn |
| Jun 30, 2025 | -23.35 Mn |
| Jun 30, 2025 | -23.35 Mn |
| Mar 31, 2025 | -56.68 Mn |
| Mar 31, 2025 | -56.68 Mn |
| Dec 31, 2024 | 38.55 Mn |
| Dec 31, 2024 | 38.55 Mn |
| Sep 30, 2024 | -55.78 Mn |
| Sep 30, 2024 | -55.78 Mn |
| Jun 30, 2024 | -4.26 Mn |
| Jun 30, 2024 | -4.26 Mn |
| Mar 31, 2024 | 73.97 Mn |
| Mar 31, 2024 | 73.97 Mn |